Danaher Corporation ($DHR) Stock Forecast: Up 5.0% Today

What is Danaher Corporation?

Danaher Corporation (NYSE: DHR) is a global conglomerate with a focus on science and technology, operating in the life sciences, diagnostics, and environmental markets. The company has been known for its consistent growth and strategic acquisitions in the biotech industry.

Why is Danaher Corporation going up?

DHR stock is up 5.0% on Jul 23, 2025 14:26

• Danaher showed strong bullish movement today following its impressive Q2 earnings, where it exceeded sales and EPS estimates, demonstrating robust performance in its biotech segment.
• The company's positive outlook for 2025, driven by biotech growth and cost discipline, has boosted investor confidence, resulting in a rise in the stock price.
• Analysts' optimistic views and projections for Danaher's key performance indicators further reinforce the positive sentiment surrounding the stock, pointing towards a promising future in the biotechnology and diagnostics sectors.

DHR Price Chart

DHR Technical Analysis

DHR News

Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline - Danaher ( NYSE:DHR )

Danaher posted Q2 sales of $5.94 billion and EPS of $1.80, beating estimates of $5.84 billion and $1.64. Biotech sales rose to $1.85 billion with 6% core growth; profit margin hit 27.3% vs. 25.5% expected.

https://www.benzinga.com/markets/earnings/25/07/46554815/danaher-lifts-2025-earnings-outlook-amid-biotech-growth-cost-discipline

Danaher ( DHR ) Q2 Earnings and Revenues Top Estimates

Danaher (DHR) delivered earnings and revenue surprises of +9.76% and +1.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2602611/danaher-dhr-q2-earnings-and-revenues-top-estimates

Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?

DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.

https://www.zacks.com/stock/news/2592367/danaher-gears-up-to-post-q2-earnings-what-lies-ahead-for-the-stock

Danaher ( DHR ) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Evaluate the expected performance of Danaher (DHR) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

https://www.zacks.com/stock/news/2588298/danaher-dhr-q2-earnings-on-the-horizon-analysts-insights-on-key-performance-measures

Trending Today

Bitcoin Cash ($BCH) Crypto Forecast: Down 5.4% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.2% Today

Ethereum ($ETH) Crypto Forecast: Down 5.6% Today

Amazon.com Inc. ($AMZN) Stock Forecast: Down 8.2% Today

Pacific Gas & Electric Co. ($PCG) Stock Forecast: Up 2.2% Today

LyondellBasell Industries NV Class A (Netherlands) ($LYB) Stock Forecast: Down 6.8% Today

Peloton Interactive Inc ($PTON) Stock Forecast: Down 7.4% Today

Avantor, Inc. ($AVTR) Stock Forecast: Down 17.0% Today

Ethena ($ENA) Crypto Forecast: Down 5.2% Today

Newell Brands Inc. ($NWL) Stock Forecast: Down 15.8% Today

Danaher Corporation Price History

21.04.2025 - DHR Stock was down 5.1%

• The bearish movement in DHR stock today could be due to profit-taking by investors following a recent increase in the stock price.
• The significant decline in the stock price over the past year might also have influenced bearish sentiment among investors.
• Insights from the P/E ratio reveal a decrease of 25.98% in the last year, potentially adding to selling pressure on the stock.
• Investor caution could be stemming from the mixed performance of the stock despite recent gains, prompting a bearish market movement today.

15.04.2025 - DHR Stock was down 5.5%

• Investors may have reevaluated their positions due to a value comparison between CVS Health and Danaher, potentially leading to a sell-off in the stock.
• The market sentiment towards the Medical Services sector might have shifted, negatively impacting Danaher's stock price.
• Uncertainty surrounding Danaher's future growth prospects or financial performance could be a contributing factor to today's bearish movement.

29.00.2025 - DHR Stock was down 8.0%

• Danaher (DHR) fell short of earnings projections for Q4, with unfavorable surprises in earnings and revenue, raising concerns about its performance.
• Manhattan Associates (MANH) provided weak FY25 guidance, which may have impacted market sentiment negatively and influenced related stocks like Danaher.
• Unusual bearish options activity on Danaher indicates that some investors have a pessimistic outlook on the stock, potentially contributing to its decline.
• The varied performance of U.S. stock futures, including some stocks experiencing declines, likely added to the downward pressure on Danaher's stock price today.

29.00.2025 - DHR Stock was down 9.9%

• Danaher's Q4 earnings missed estimates, with a negative surprise on both earnings and revenue, indicating potential challenges in the company's financial performance.
• The decline in the diagnostics segment impacted overall earnings performance, highlighting a specific area of weakness within the company.
• The unusual options activity showing a bearish stance on Danaher suggests that investors with significant capital are taking a pessimistic view on the stock, potentially contributing to the downward pressure on its price.
• Overall, the combination of earnings miss, segment lag, and bearish sentiment from investors likely led to the bearish movement in Danaher's stock today.

15.00.2025 - DHR Stock was down 0.7%

• Although Danaher has historically outperformed the market, the recent bearish movement could be due to investors capitalizing on gains following a period of growth.
• Market dynamics or industry-specific developments impacting companies in a similar vein as Danaher might be influencing the stock's downturn.
• Given the current market environment, investors could be reallocating their investments, possibly exploring other industries or asset classes, leading to a decrease in Danaher's share value.

04.03.2025 - DHR Stock was down 6.1%

• Unusual bearish options activity observed for Danaher (DHR) indicates a significant number of investors are betting on a downward movement in the stock price.
• The bearish stance taken by investors could be due to concerns about the company's financial performance, industry outlook, or broader market conditions.
• This bearish movement may also be influenced by macroeconomic factors or specific company-related news that has impacted investor sentiment towards Danaher.

04.03.2025 - DHR Stock was down 7.4%

• Today's bearish movement in DHR stock is linked to concerns regarding the performance of its Life Sciences and Biotechnology units.
• Despite the positive performance in the clinical diagnostics business and the recent Abcam acquisition, challenges in certain segments appear to have impacted investor sentiment.
• Unusual options activity suggesting a bearish stance from investors with significant capital may have intensified the downward pressure on DHR stock.
• Investors are closely observing Danaher's efforts to address the issues in its underperforming units and leverage opportunities in its thriving businesses to restore market confidence and reverse the bearish trend.

22.06.2025 - DHR Stock was down 1.3%

• Earnings and revenue figures for Q2 exceeded expectations for Danaher (DHR), with market volatility potentially linked to concerns in the Life Sciences area.
• Strong performance in the Biotechnology & Diagnostics divisions alongside the recent acquisition of Abcam are viewed as factors that could drive future growth for the company.
• Analyst commentary on Q2 performance metrics for Danaher (DHR) may have impacted market sentiment, contributing to the stock's downward movement today.

22.03.2025 - DHR Stock was up 5.6%

• Danaher (DHR) surpassed both earnings and revenue projections for the first quarter of 2025, demonstrating robust financial results.
• The Biotechnology segment's strength is believed to have contributed significantly to the favorable earnings outcome, compensating for weaknesses in the Diagnostics and Life Sciences divisions.
• Market analysts had set high anticipations for Danaher's Q1 earnings, expecting an outperformance based on the company's historical performance and market positioning.
• Danaher's consistent outperformance over the past decade, boasting an average annual return of 12.55%, is indicative of the company's strong long-term growth strategy and market resilience.

22.03.2025 - DHR Stock was up 5.8%

• Danaher (DHR) reported strong Q1 earnings, surpassing both earnings and revenue estimates, which likely contributed to the bullish movement in the stock.
• Despite a 1% year-over-year sales decrease in the Life Sciences segment, the overall performance beat expectations, indicating resilience in other segments.
• Analysts were optimistic about DHR's Q1 earnings, particularly in the Biotechnology segment, which likely boosted investor confidence and drove the stock higher.
• The consistent outperformance of Danaher over the past decade, with an average annual return of 12.55%, has also likely attracted investors to the stock, further fueling its bullish movement.

10.03.2025 - DHR Stock was up 5.7%

• The bullish movement in DHR stock today can be attributed to:
• Positive analyst sentiment and upgrades, indicating growing confidence in the company's performance and potential.
• Strength in the clinical diagnostics business, driven by recent acquisitions like Abcam and shareholder-friendly policies, boosting investor optimism.
• Despite concerns in the Life Sciences and Biotechnology units, the overall positive outlook for the company's core businesses is overshadowing these challenges, leading to the bullish momentum in the stock.

23.06.2025 - DHR Stock was up 5.0%

• Danaher showed strong bullish movement today following its impressive Q2 earnings, where it exceeded sales and EPS estimates, demonstrating robust performance in its biotech segment.
• The company's positive outlook for 2025, driven by biotech growth and cost discipline, has boosted investor confidence, resulting in a rise in the stock price.
• Analysts' optimistic views and projections for Danaher's key performance indicators further reinforce the positive sentiment surrounding the stock, pointing towards a promising future in the biotechnology and diagnostics sectors.